Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Knight Therapeutics Inc. Announces Election of Directors

MarketWire Canada June 16, 2016

Knight Therapeutics Completes Previously Announced Bought Deal of Common Shares, Including Exercise of Over-Allotment Option, for $230 million

MarketWire Canada June 2, 2016

Knight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City

MarketWire Canada May 31, 2016

Knight Reports First Quarter 2016 Results

Marketwired May 10, 2016

Knight Blooms at Healthcare Investor Conference in Toronto

Marketwired April 25, 2016

Knight Receives NOD from Health Canada for ATryn(R)

Marketwired April 25, 2016

Knight Finds EMPAthetic Partner for Neuragen(R) in the Middle East

Marketwired April 25, 2016

Knight Reports Fourth Quarter and Year-Ended December 31, 2015 Results

Marketwired March 24, 2016

Knight Receives Dividend From Medison

Marketwired March 23, 2016

Knight Partner Profounda Inc. Launches Impavido in U.S.

Marketwired March 22, 2016

Profounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States

Canada NewsWire March 22, 2016

Knight Obtains Impavido Worldwide Rights

Marketwired March 15, 2016

Knight Breaks Glass on Medimetriks Partnership

Press Releases February 17, 2016

Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE(R)

Marketwired February 1, 2016

Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE®

PR Newswire February 1, 2016

INTEGA Skin Looks GUD to Knight

Marketwired January 25, 2016

Knight Loan to Extenway Impaired

Marketwired December 22, 2015

Knight Takes Right Angle With 60 Degrees Pharmaceuticals LLC

Marketwired December 11, 2015

CRH Makes GUD on Knight Secured Loan

Marketwired November 25, 2015

Knight to Present at the TD Securities Technology & Healthcare Conference in Toronto

Marketwired November 17, 2015